MILAN, Italy and DAYTON, Ohio, Feb. 26, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced positive results of a pilot pharmacokinetic study of EUR-1025, the Company’s proprietary once-a-day (QD) oral formulation of ondansetron hydrochloride. Ondansetron hydrochloride is marketed under the brand name Zofran(r) by GlaxoSmithKline for the treatment and prevention of chemotherapy-induced nausea and vomiting.
